#drug pricing

Neither does the focus on Pharmacy Benefits Managers.

60 groups sign a letter to state insurance commissioners and attorneys general asking them to reverse the policy.

Stocks of drug companies are rising—and that’s not a good sign for consumers.

The FDA commissioner wants drugmakers to “end the shenanigans.”

He also jacked up the price of an AIDS-related med 5,000 percent and offered $5K for a lock of Hillary Clinton’s hair.

He’ll oversee the FDA, Medicare and Medicaid at a time when soaring drug prices remain a contentious political topic.

Cuts to the 340B program could lead to cutbacks—and even closings—at hospitals and HIV care providers.

U.S. lawmakers say appointing Azar is like putting “the pharmaceutical fox in charge of the health care henhouse.”

Cheaper, generic versions of PrEP are also becoming available in the Canadian province.

AIDS activists urge the N.Y. attorney general to investigate possible antitrust violations regarding the HIV med used as PrEP.

The company is losing its exclusive rights to two HIV drugs: Reyataz and Sustiva.

AIDS activists had protested Shkreli after he jacked up the price of a 62-year-old med by 5,000%.

The Trump administration calls for fewer of the drug coverage reviews that ensure that health plans don’t discriminate.

Outlined in a Health Affairs Blog post, the recommendations come from the Treatment Action Group and the Fair Pricing Coalition.

But do Scott Gottlieb’s interests lie with drugmakers or patients?